The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
RRIA (Rapid Response Innovation Awards), 2013Role of GSK-3beta in Parkinson’s Disease
The protein GSK-3beta has not previously been linked to Parkinson’s disease (PD). Recently, we have studied pre-clinical models with high levels of GSK-3beta throughout the brain. At a younger age [up...
-
MJFF Research Grant, 2013Validation and Characterization of Exosomal Alpha-synuclein as a Diagnostic Marker for Parkinson’s Disease
Parkinson’s disease (PD) is characterized by aggregation of the intracellular alpha-synuclein protein and subsequent neurodegeneration. Recent findings suggest that extracellular alpha-synuclein forms...
-
Rapid Response Innovation Awards, 2012Polyglutamine Repeats and Parkinson Disease
Objective/Rationale:
Trinucleotide repeat expansion is a gene mutation where the codons (the groups of DNA components that correspond to amino acids) exceed the maximum of a certain gene... -
Dyskinesia LEAPS, 2012Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Objective/Rationale:
Dyskinesia is a term used to describe involuntary movements that develop as side effects of dopamine drugs used to treat Parkinson's disease. Dyskinesias are frequent and... -
Research Grant, 2013Ubiquitous, Inexpensive Non-invasive Technologies for Objective Detection and Monitoring of Parkinson’s Symptoms
Objective/Rationale:
For doctors to diagnose and treat Parkinson’s, they need reliable tests. Unfortunately, testing the symptoms of Parkinson’s at a specialist’s office/clinic is expensive and time... -
Research Grant, 2013Prion-like Dissemination of Synuclein Pathology: A Non-human Study
Objective/Rationale:
Parkinson’s disease (PD) is characterized by the loss of midbrain dopaminergic neurons and the presence of aggregates named Lewy bodies. This pathology is believed to drive the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.